Jason Haas - 31 Mar 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Financial Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
31 Mar 2024
Net transactions value
-$24,228
Form type
4
Filing time
02 Apr 2024, 16:54:49 UTC
Previous filing
02 Nov 2023
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +2,000 +14% 15,951 31 Mar 2024 Direct F1
transaction SYRS Common Stock Options Exercise +13,333 +84% 29,284 31 Mar 2024 Direct F1
transaction SYRS Common Stock Tax liability $24,228 -4,732 -16% $5.12 24,552 01 Apr 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -2,000 -33% $0.000000 4,000 31 Mar 2024 Common Stock 2,000 Direct F3, F4
transaction SYRS Restricted Stock Units Options Exercise $0 -13,333 -33% $0.000000 26,667 31 Mar 2024 Common Stock 13,333 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding upon the release of restricted stock units.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
F5 Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.